Absci (NASDAQ:ABSI – Get Free Report) and Opus Genetics (NASDAQ:IRD – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations.
Earnings & Valuation
This table compares Absci and Opus Genetics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Absci | $2.80 million | 530.15 | -$115.18 million | ($0.80) | -10.81 |
| Opus Genetics | $14.20 million | 33.35 | -$49.59 million | ($1.35) | -4.24 |
Profitability
This table compares Absci and Opus Genetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Absci | -7,756.38% | -61.71% | -54.52% |
| Opus Genetics | -1,091.82% | -338.88% | -150.13% |
Risk & Volatility
Absci has a beta of 2.42, indicating that its share price is 142% more volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and price targets for Absci and Opus Genetics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Absci | 1 | 0 | 9 | 0 | 2.80 |
| Opus Genetics | 1 | 1 | 15 | 1 | 2.89 |
Absci presently has a consensus price target of $13.71, indicating a potential upside of 58.55%. Opus Genetics has a consensus price target of $11.69, indicating a potential upside of 104.05%. Given Opus Genetics’ stronger consensus rating and higher probable upside, analysts clearly believe Opus Genetics is more favorable than Absci.
Insider & Institutional Ownership
52.0% of Absci shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 10.5% of Absci shares are owned by insiders. Comparatively, 11.7% of Opus Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Opus Genetics beats Absci on 9 of the 15 factors compared between the two stocks.
About Absci
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.
About Opus Genetics
Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.
Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.
